Bone's dark side: mutated osteoblasts implicated in leukemia.

Amir Schajnovitz, David T Scadden

Open access · bronzeAbstract readComment

In one paragraph

Article in Cell research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

0.4field-weighted citation impact, top 38% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches.The Journal of experimental medicine · 2018
Review
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?International journal of molecular sciences · 2016
Review
Oral manifestations of leukemia as part of early diagnosis.Hematology, transfusion and cell therapy
Review

4 · The record

Corrections and comments

Comment on
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts.2014

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amir Schajnovitz1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA [2] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA [3] Harvard Stem Cell Institute, Cambridge, MA 02138, USA.

David T Scadden1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA [2] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA [3] Harvard Stem Cell Institute, Cambridge, MA 02138, USA.

Harvard Stem Cell Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone-lining osteolineage cells were previously implicated as contributors to hematological disorders and malignancies. A recent report in Nature now demonstrates that a specific mutation in mouse collagen-expressing osteoblastic cells leads to MDS and AML with 100% penetrance and is associated with strikingly similar findings in human patients.

Indexed as

Animalsbeta CateninCell Transformation, NeoplasticFemaleHumansLeukemia, Myeloid, AcuteMaleMutationOsteoblastsbeta Catenin

Identifiers

PMID24589711

DOI10.1038/cr.2014.26

PMCPMC3975504

OpenAlexW2004110903

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.